Literature DB >> 6519153

Plasma kinetics of dipyrone metabolites in rapid and slow acetylators.

M Levy, D Flusser, E Zylber-Katz, L Granit.   

Abstract

The pharmacokinetics of the dipyrone metabolites 4-methylaminoantipyrine (MAA), 4-aminoantipyrine (AA), 4-formylaminoantipyrine (FAA) and 4-acetylaminoantipyrine (AAA) were evaluated following the administration of a single oral 1.0 g dose of dipyrone to 23 healthy volunteers. Twelve were slow and 11 were rapid acetylators as previously determined by dapsone phenotyping. For MAA and FAA the mean peak plasma concentrations were 10.5 +/- 2.8 micrograms/ml and 2.1 +/- 0.8 micrograms/ml and the half-lives were 3.3 +/- 1.0 and 10.1 +/- 1.8 h, respectively. No significant difference was found between rapid and slow acetylators in MAA and FAA kinetics. For AA, the mean peak plasma concentrations were 2.7 +/- 0.6 and 1.6 +/- 0.7 micrograms/ml (p less than 0.01), the peak times 6.7 +/- 2.1 and 3.1 +/- 1.1 h (p less than 0.01) and the half-lives were 5.5 +/- 1.0 and 3.8 +/- 1.2 h in slow and rapid acetylators, respectively. For AAA, the mean peak plasma concentrations were 1.6 +/- 0.4 and 4.4 +/- 1.1 micrograms/ml (p less than 0.01) and the peak time 16.1 +/- 5.1 and 10.0 +/- 2.6 h (p less than 0.01) in slow and rapid acetylators, respectively. There was no difference in the elimination half-life between the two groups (10.6 +/- 2.2 h). Thus, it has been demonstrated that the AAA/AA ratio is an indicator of the acetylation phenotype, as it is closely correlated with that determined by dapsone (r = 0.895, p less than 0.0005).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6519153     DOI: 10.1007/bf00549594

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  In vivo formation of 4-formylaminoantipyrine as a new metabolite of aminopyrine. I.

Authors:  A Noda; T Goromaru; N Tsubone; K Matsuyama; S Iguchi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1976-07       Impact factor: 1.645

2.  [Comparative study on the problem of absorption and metabolism of the pyrazolone derivative metamizole, in man after oral and intramuscular administration].

Authors:  R Weiss; J Brauer; U Goertz; R Petry
Journal:  Arzneimittelforschung       Date:  1974-03

3.  Simultaneous determination of dipyrone metabolites in plasma by high-performance liquid chromatography.

Authors:  E Z Katz; L Granit; D E Drayer; M Levy
Journal:  J Chromatogr       Date:  1984-02-10

4.  Epidemiological evaluation of rare side-effects of mild analgesics.

Authors:  M Levy
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

5.  The measurement of plasma concentration of aminopyrine and its metabolites in man.

Authors:  T Goromaru; K Matsuyama; A Noda; S Iguchi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1978-01       Impact factor: 1.645

6.  The acetylator phenotype of patients with systemic lupus erythematosus.

Authors:  M M Reidenberg; J H Martin
Journal:  Drug Metab Dispos       Date:  1974 Jan-Feb       Impact factor: 3.922

7.  [Biopharmaceutical and pharmacokinetic studies on metamizol-14C (Novalgin 14C) given to rats, dogs and men].

Authors:  O Christ; H M Kellner; G Ross; W Rupp; A Schwarz
Journal:  Arzneimittelforschung       Date:  1973-12

8.  The design of a study of the drug etiology of agranulocytosis and aplastic anemia. A report from the International Agranulocytosis and Aplastic Anemia Study.

Authors: 
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 9.  Kinetics and metabolism of pyrazolones (propyphenazone, aminopyrine and dipyrone).

Authors:  M Volz; H M Kellner
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

10.  Effects of dipyrone on prostaglandin production by human platelets and cultured bovine aortic endothelial cells.

Authors:  A Eldor; G Polliack; I Vlodavsky; M Levy
Journal:  Thromb Haemost       Date:  1983-04-28       Impact factor: 5.249

View more
  13 in total

1.  Influence of food on the pharmacokinetics of dipyrone.

Authors:  D Flusser; E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  The acetylation phenotype: does it contribute to the non-linearity of the metabolite pharmacokinetics of metamizol?

Authors:  N Bacracheva; V Vlahov
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

3.  Formation and excretion of dipyrone metabolites in man.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Plasma protein binding of dipyrone metabolites in man.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Clinical pharmacokinetics of dipyrone and its metabolites.

Authors:  M Levy; E Zylber-Katz; B Rosenkranz
Journal:  Clin Pharmacokinet       Date:  1995-03       Impact factor: 6.447

Review 6.  Pyrazolone derivatives.

Authors:  R N Brogden
Journal:  Drugs       Date:  1986       Impact factor: 9.546

7.  Excretion of dipyrone metabolites in human breast milk.

Authors:  E Zylber-Katz; N Linder; L Granit; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Effect of age on the pharmacokinetics of dipyrone.

Authors:  E Zylber-Katz; L Granit; J Stessman; M Levy
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

9.  Pharmacokinetics of metamizol metabolites in healthy subjects after a single oral dose of metamizol sodium.

Authors:  V Vlahov; M Badian; M Verho; N Bacracheva
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

10.  Dose evaluation of intravenous metamizole (dipyrone) in infants and children: a prospective population pharmacokinetic study.

Authors:  Victoria C Ziesenitz; Frédérique Rodieux; Andrew Atkinson; Carole Borter; Julia A Bielicki; Manuel Haschke; Urs Duthaler; Fabio Bachmann; Thomas O Erb; Nicolas Gürtler; Stefan Holland-Cunz; Johannes N van den Anker; Verena Gotta; Marc Pfister
Journal:  Eur J Clin Pharmacol       Date:  2019-08-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.